Prosecution Insights
Last updated: May 29, 2026

Xenon Pharmaceuticals Inc.

8 pending office actions • 4 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
6
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
3
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (3)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (38%)
0
Easy (0%)
5
Unknown (62%)

Rejection Statute Mix

BucketCases
§103 only3 (38%)
No statute on record5 (62%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SOROUSH, LAYLA 3 40.2% +43.6%
CARCANAGUE, DANIEL R 1 80.8% +24.5%
HUTTER, GILLIAN A 1 54.9% +46.1%
SZNAIDMAN, MARCOS L 1 36.9% +15.9%
ROZOF, TIMOTHY R 1 72.6% +24.0%
LEE, CHIHYI NMN 1 32.5% +62.8%

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18746981 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS CARCANAGUE, DANIEL R 196d overdue
18540582 SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR ROZOF, TIMOTHY R 67d overdue
18415139 METHODS FOR TREATING PAIN SZNAIDMAN, MARCOS L 19d overdue
18679045 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 3d overdue
18330100 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS LEE, CHIHYI NMN 13d
19094303 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 14d
18648049 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 28d
18603554 CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS HUTTER, GILLIAN A 46d

Top Art Units

Art UnitApps
1622 3
1625 2
1628 2
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19094303 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 1622 Other Non-Final OA 14d Pending Mar 28, 2025
18746981 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS CARCANAGUE, DANIEL R 1621 Other Non-Final OA 196d overdue Pending Jun 18, 2024
18679045 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 1622 Other Non-Final OA 3d overdue Pending May 30, 2024
18648049 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 1622 Other Non-Final OA 28d Pending Apr 26, 2024
18603554 CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS HUTTER, GILLIAN A 1625 §103 Final Rejection 46d Pending Mar 13, 2024
18415139 METHODS FOR TREATING PAIN SZNAIDMAN, MARCOS L 1628 §103 Non-Final OA 19d overdue Pending Jan 17, 2024
18540582 SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR ROZOF, TIMOTHY R 1625 Other Final Rejection 67d overdue Pending Dec 14, 2023
18330100 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS LEE, CHIHYI NMN 1628 §103 Non-Final OA 13d Pending Jun 06, 2023

Managing Xenon Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month